Compounding at Scale: Verifying Peptide Purity and COAs

News headlines about compounded GLP-1 receptor agonists often focus on patient safety and FDA rules. For the research community, those headlines point to a more immediate, bench-side problem. When a peptide is made quickly and in huge quantities to meet demand, the quality of the final powder in your vial can vary. This affects the reliability of your research data from the first step.

Compounding at Scale Is a Different Game

Traditional compounding is like a skilled tailor making a custom suit. A small pharmacy mixes a specific recipe for one person. The large-scale outsourcing now happening for popular peptides is more like a factory ramping up production of a standard jacket. The active ingredient, the peptide itself, is the same string of amino acids. The process, however, is different.

Instead of a single, tightly controlled pharmaceutical plant, the raw peptide synthesis might be sent to one of several large contract labs. The final step, putting that powder into vials, happens at another facility. Each handoff is a point where consistency can drift. The FDA's concern is that these operations, while following compounding rules, are functioning like drug manufacturers without the same long-term oversight.

What This Means for Your Vials and Reconstitution

For a researcher, the term "purity" on a certificate of analysis (COA) is everything. With rapidly produced compounds, you have to look closer at that number. A high purity reading (like 98%) is good, but it doesn't tell the whole story. The other 2% matters.

• Byproducts: These are leftover bits from the chemical soup used to build the peptide chain. They can look similar to your target molecule, making them hard to separate.
• Degradation products: These are fragments of your peptide that broke during synthesis or handling. They are inactive junk.
• Salt forms: Peptides are often shipped as a salt, like a hydrochloride or acetate. The type and amount of salt affects the powder's weight and your reconstitution math.

If your vial contains more of these "other things," the actual concentration of active peptide after you reconstitute it will be lower than you think. Your dosing calculations become a guess. This introduces a variable that can skew results across an entire experiment.

Bench-Side Steps for Protecting Your Work

You cannot control how a peptide was made upstream, but you can control what happens at your bench. This is where diligence pays off.

First, verify your reconstitution. When you add bacteriostatic water to the vial, you are creating a solution. If the starting powder had a high load of bacterial endotoxins (waste from bacterial contamination during synthesis), it can cause issues. Using sterile, endotoxin-free water is a baseline requirement. Always filter your reconstituted solution through a 0.22 micron syringe filter if you have any doubt about the source purity.

Second, reevaluate your storage. A peptide that is 99% pure is more stable than one that is 95% pure. The impurities can sometimes speed up degradation. Aliquot your reconstituted peptide into single-use, low-bind microcentrifuge tubes immediately. Flash-freeze them on dry ice. Store them at -20°C or -80°C. Do not keep your working stock in the fridge for weeks. Every freeze-thaw cycle is a stress test your peptide may fail.

The Sourcing Question

The community relies on a network of vendors. The source of the raw peptide powder is often opaque. It may come from a large overseas supplier who sells to multiple compounding pharmacies. This means the same foundational material could be in vials from different vendors.

Your best tool is asking questions. A reputable vendor should be able to provide a COA that details not just purity (via HPLC), but also amino acid sequence confirmation (via mass spec). They should disclose the salt form. If a vendor cannot provide this documentation, the risk to your research integrity increases. The convenience of a popular compound should not outweigh the need for traceable, consistent starting material. Your data depends on it.

Frequently asked questions

How does compounding scale affect peptide purity?

Large-scale outsourcing can lead to batch-to-batch variability in synthesis and purification, potentially increasing levels of impurities like truncated sequences or residual salts compared to tightly controlled pharmaceutical manufacturing.

What should I look for on a COA for a compounded peptide?

Verify purity via HPLC (>95% is a common target), confirm the molecular identity with mass spectrometry data, and check the stated salt form to ensure accurate reconstitution calculations.

What is the best storage practice for reconstituted GLP-1 peptides?

Aliquot into single-use, low-bind tubes immediately after reconstitution, flash-freeze, and store at -20°C or -80°C. Avoid repeated freeze-thaw cycles which can cause degradation.

Prompted by this coverage at Google News →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

What the research community gets wrong about compounded GLP-1 research samples

• A high purity number is not the whole story. A COA that reads 98% by HPLC still leaves 2% that matters. Published analyses of follow-on and compounded GLP-1 material have found extra impurities that a single purity percentage does not describe, including truncated chains and amino acid deletions or additions. Read the full impurity table, not just the headline figure.
• Same peptide name does not mean same material. Two vials can both say semaglutide and still differ. Studies comparing follow-on GLP-1 products to the originator reported new impurity patterns, high molecular weight species, trace metals, counterions, and residual solvents. Treat each lot as its own unknown until the paperwork says otherwise.
• The salt form changes your math, not just the label. Peptides ship as a salt such as acetate or hydrochloride. That salt adds weight, so the actual peptide mass in the vial can be lower than the stated fill. If you skip the salt correction, your reconstituted concentration will be off from the first pipette.
• Purity and stability are linked at the bench. Impurities can speed up breakdown in solution. Degradation work on semaglutide using LC-HRMS found that factors like pH and temperature drove the formation of multiple known impurities. A less pure starting powder can drift faster once it is in water, so storage habits matter more, not less.
• Mass spec is a separate check from HPLC. HPLC purity does not confirm the peptide is the correct sequence. Identity needs mass spectrometry. A COA without mass spec data leaves the identity of your material unverified.

From our bench: If you run compounded GLP-1 material, we want your real numbers. Take one lot, note the stated fill weight and the salt form from the COA, then record the concentration you calculated after correcting for salt content versus the naive concentration you would have used without it. Tell us the two values, the peptide, and the salt form. Firsthand data from your own vials helps other researchers see how large the salt correction really is. We publish observations, not invented figures.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Hach et al., Pharmaceutical Research 2024 , Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (PMID 39379664)
5. Kopp et al., Pharmaceutical Research 2026 , Impurities and Potential Immunogenicity Associated With Follow-on and Compounded GLP-1 Receptor Agonists (PMID 42533250)
6. Malgave et al., European Journal of Pharmaceutics and Biopharmaceutics 2025 , Solution state degradation of semaglutide using LC-HRMS (PMID 40490042)